Internalisation of integrin-bound extracellular matrix modulates invasive carcinoma cell migration

Montserrat Llanses Martinez,Keqian Nan,Zhe Bao,Rachele Bacchetti,Shengnan Yuan,Joe Tyler,Xavier Le Guezennec,Frédéric A. Bard,Elena Rainero

DOI: https://doi.org/10.1101/2024.01.11.575153

2024-01-14

Abstract:The interaction between cancer cells and the extracellular matrix (ECM) plays a pivotal role in tumour progression. While the extracellular degradation of ECM proteins has been well characterised, ECM endocytosis and its impact on cancer cell progression, migration and metastasis is poorly understood. ECM internalisation is increased in invasive breast cancer cells, suggesting it may support invasiveness. Here we developed a high-content screening assay to study ECM uptake. We identified that mitogen-activated protein kinase (MAPK) family members, MAP3K1 and MAPK11 (p38β), and the protein phosphatase 2 (PP2) subunit PPP2R1A were required for the internalisation of ECM-bound α2β1 integrin. Furthermore, α2β1 integrin was necessary for macropinocytosis of soluble dextran, identifying it as a novel and targetable regulator of macropinocytosis in cancer. Moreover, disruption of α2 integrin, MAP3K1, MAPK11 and PP2R1A-mediated ECM internalisation significantly impaired cancer cell migration and invasion in 2D and 3D culture systems. Finally, α2β1 integrin and MAP3K1 expression were significantly upregulated in pancreatic tumours and correlated with poor prognosis in pancreatic cancer patients. Strikingly, MAP3K1, MAPK11, PPP2R1A and α2 integrin expression were higher in chemotherapy-resistant tumours in breast cancer patients. Our results identified the α2β1 integrin/p38 signalling axis as a novel regulator of ECM endocytosis, which drives invasive migration and tumour progression.

Cancer Biology

What problem does this paper attempt to address?

This paper aims to explore the role of extracellular matrix (ECM) endocytosis in the migration of invasive cancer cells and its regulatory mechanisms. Specifically, the researchers focused on how integrin - bound ECM affects the progression, migration, and metastasis of cancer cells through endocytosis, especially this phenomenon is more prominent in breast cancer cells. The study found that MAP3K1, MAPK11 (p38β), and the subunit PPP2R1A of protein phosphatase 2A (PP2A) are key regulators of ECM endocytosis, and α2β1 integrin is an indispensable component in this process. It is not only involved in the macropinocytosis of ECM but also promotes the invasive migration of cancer cells.

The main issues of the study can be summarized as follows:
1. **The role of ECM endocytosis in the invasive migration of cancer cells**: Explore how ECM endocytosis supports the invasive migration of cancer cells, especially in breast cancer cells.
2. **The regulatory mechanism of ECM endocytosis**: Identify and verify the roles of MAP3K1, MAPK11, PPP2R1A, and α2β1 integrin in the ECM endocytosis process.
3. **The relationship between ECM endocytosis and cancer cell migration**: Verify through experiments how these regulatory factors affect the migration ability of cancer cells in two - dimensional and three - dimensional culture systems.
4. **Clinical significance**: Explore the expression of these regulatory factors in different cancer types and their relationship with patient prognosis, especially the association between their high expression in pancreatic cancer and poor prognosis, as well as their potential role in breast cancer chemotherapy resistance.

Through these studies, the paper reveals the α2β1 integrin/p38 signaling axis as a new regulatory mechanism of ECM endocytosis, which drives invasive migration and tumor progression and may become a target for future therapeutic interventions.